Cullinan Therapeutics, Inc. CGEM Proceeds From Net Issuance Of Common Stock Under Equity Based Compensation Plans
Proceeds From Net Issuance Of Common Stock Under Equity Based Compensation Plans at other companies
Other financials
Where this comes from
Reported directly by Cullinan Therapeutics, Inc. in its filing.
Tagged under the XBRL concept cgem:ProceedsFromNetIssuanceOfCommonStockUnderEquityBasedCompensationPlans.
The official record: Cullinan Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cullinan Therapeutics, Inc.'s proceeds from net issuance of common stock under equity based compensation plans.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cullinan Therapeutics, Inc.'s proceeds from net issuance of common stock under equity based compensation plans?
- Cullinan Therapeutics, Inc. (CGEM) reported proceeds from net issuance of common stock under equity based compensation plans of $380K in Q1 2026.
- What is the long-term trend for Cullinan Therapeutics, Inc.'s proceeds from net issuance of common stock under equity based compensation plans?
- Over 2 years (2023 to 2025), Cullinan Therapeutics, Inc.'s proceeds from net issuance of common stock under equity based compensation plans has grown at a 42.2% compound annual growth rate (CAGR), from $538K to $1.09M.
- What does proceeds from net issuance of common stock under equity based compensation plans mean?
- This metric captures the net cash inflows resulting from the issuance of common stock to employees or directors as part of equity-based compensation programs, such as stock option exercises. It represents the capital generated when personnel purchase shares under these incentive plans. This figure provides insight into the cash impact of employee equity participation and the dilution management of the company's capital structure.